Stephen Davies Appointed Vice President, Eisai Strategic Information Systems at Eisai Inc.

WOODCLIFF LAKE, N.J., Aug. 27, 2018 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Stephen Davies as Vice President, Eisai Strategic Information Systems. Mr. Davies will be responsible for leading the information technology (IT) function for Eisai's Americas region, as well as the company's global clinical and global regulatory solutions. He will also serve as a member of Eisai's Executive Committee for the Americas, and on the company's Global IT Steering Committee.

Mr. Davies, who has over 20 years of pharmaceutical industry IT experience, will be responsible for directing the company's IT operations, application development, maintenance, technology infrastructure, consulting and advisory services for all of Eisai's business units in the Americas.

"Given his extensive experience as a global enterprise IT leader in the life sciences industry, Stephen will be a tremendous asset for Eisai," said Shaji Procida, President & Chief Operating Officer of Eisai Inc. "We are breaking through in all areas of our business, and innovative technology solutions will play a vital role in helping to propel Eisai into our next phase of expected growth."

Mr. Davies joins Eisai from Gartner Inc., where he spent the past four years as Research Director, Life Sciences. In this role, he focused on delivering technology-related insight to help the Chief Information Officer and senior IT leaders develop strategic decisions related to IT investments, projects and strategies. Prior to Gartner, Mr. Davies served in executive IT roles at Savient Pharmaceuticals, Inc., Imclone Systems, and Boehringer Ingelheim.  

Mr. Davies earned a Bachelor of Arts degree in Communications and a minor in Computer Science from Rowan University. Over the course of his career, Mr. Davies has had over 35 research documents published.

Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, manufacturing and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at

Eisai Co. Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit

Media Inquiries                        

Investor Inquiries              

Patricia Councill                           

Alex Scott

Eisai Inc.                                    

Eisai Inc.





SOURCE Eisai Inc.

Type Press Release

Date Released August 27, 2018

May 9, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Apr 26, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody...

Apr 7, 2022

Eisai stands with people living with Alzheimer’s disease (AD), health care professionals and other members of our AD community. We respect that the Centers for Medicare and Medicaid Services...

Alerts - Release page
* Required Fields